Stroke attack has been a widely feared disease among all. A recent study focused on atrial fibrillation (AF) patients who have a sheer risk of stroke has been evolved with some surprising and unbelievable measures. The study hints that those of AF patients who have already gone through ablation, instead of having prevention from a stroke due to long-term aspirin based medications, actually have some risk. They carry a higher chance of bleeding which can turn into similar kind of movements causing strokes.

According to Science Daily, a team of researchers belonging from the Intermountain Medical Center Heart Institute in Salt Lake City came up with a new theory. It briefs long-term aspirin medication-based therapy is not actually beneficial to those of AF patients who have been operated on the catheter ablation. Jared Bunch, MD, the study's lead author and director of Heart Rhythm Research at the Intermountain Medical Center Heart Institute stated: "What was unknown was if aspirin was a safe and effective stroke prevention treatment after an ablation in lower-risk AF patients." He further added that, as a medical tradition, lower-risk AF patients have long been treated with long-term aspirin based treatment without any dependable or trustworthy proofs.

EurekAlert noted that, for the research purpose, Bunch and his fellow researchers examined a total of 4,124 lower-risk patients who already went through catheter ablation. The team investigated them based on the effects of long-term aspirin therapy which they were already part of and the outcome that they can trust upon as a potential stroke prevention. The findings were surprising, which hinted that these AF patients have had higher risks for being suffered from stroke by gastrointestinal bleeding and genitourinary bleeding than those of AF patients haven't been treated with any measures.

This came as a superlative new horizon in terms of stroke treatment. The study was presented at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions which held in Chicago on May 13, 2017.